Anrotinib is effective for small cell lung cancer patients, and it is recommended that patients strictly follow the doctor’s instructions to use the drug in a standardized way.
Anrotinib is a commonly used targeted drug in clinic, which is a multi-target tyrosine kinase inhibitor, can effectively inhibit the growth of tumor cells and inhibit the generation of tumor blood vessels, thus reducing the tumor foci, improving the prognosis of the disease, improving the quality of life of patients, and prolonging the life span of patients with small-cell lung cancer.
However, due to the individual variability of small cell lung cancer patients, there is no absolute most effective Anrotinib, which needs to be used under the guidance of a doctor, and should not be used without authorization, and adverse reactions such as high blood pressure, bleeding, etc. are recommended to seek medical treatment as soon as possible, and the use of the drug is prohibited for people with drug allergy.